查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1566974

細胞毒性藥物市場：按藥物類型、應用、給藥途徑、分銷管道分類：2024-2033年全球機會分析和產業預測

Cytotoxic Drug Market By Drug Type , By Application By Route of Administration By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 245 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年細胞毒性藥物市值為158億美元，預計2024年至2033年複合年成長率為2.1%，到2033年達到195億美元。

細胞毒性藥物是透過直接作用於 DNA 或抑制蛋白質生物合成來抑制癌細胞生長的化療藥物。然而，它們的使用通常會帶來嚴重的副作用，因為它們也會作用於經常分裂的健康細胞，例如骨髓、胃腸道和毛囊中的細胞。儘管有這些挑戰，細胞毒性藥物在各種癌症的治療中仍然至關重要，有助於提高存活率並改善疾病管理。

全球細胞毒性藥物市場的成長主要是由癌症盛行率的驚人成長所推動的。據世界衛生組織 (WHO) 稱，癌症是第一大死因，預計 2020 年將有約 1,000 萬人死亡。此外，老年人口的快速增加也對全球市場的成長做出了重大貢獻。這是因為老年人更容易罹患癌症，導致對癌症治療的需求增加。此外，提高對癌症早期檢測和治療的認知是市場的關鍵驅動力。美國癌症協會強調，早期診斷的癌症患者五年存活率為90%，而晚期診斷的患者五年存活率為20%；我們強調細胞毒性藥物在發現和後續使用中的重要性；治療。人們越來越注重開發針對個別患者遺傳特徵的標靶細胞毒性療法，以提高治療效果並最大限度地減少副作用，這進一步推動了市場成長。此外，口服細胞毒性藥物因其方便性和易於給藥而受到高度歡迎，能夠提高患者的依從性和生活品質，從而促進市場成長。然而，與細胞毒性藥物相關的副作用，如噁心、脫髮和骨髓抑制，限制了它們的使用，從而阻礙了全球市場的成長。此外，人們對更有效治療方法的認知不斷增強，例如標靶治療、免疫療法和其他創新的癌症治療方法，很可能會減少對傳統細胞毒性藥物的需求，導致市場這成為阻礙因素。相反，藥物配方和藥物輸送系統的創新，以提高細胞毒性藥物的功效和安全性，預計將為預測期內全球市場的成長提供有利的機會。例如，最近的研究表明，細胞毒性藥物的新配方（例如脂質體阿黴素）可以減少副作用並改善患者的治療效果。臨床試驗表明，這些先進的製劑可以將腫瘤部位的藥物傳遞增強 30-40%。

全球細胞毒性藥物市場按藥物類型、應用、給藥途徑、分銷管道和區域細分。依藥物類型分為烷化劑、抗腫瘤抗生素、抗代謝藥、植物生物鹼等。依用途分為乳癌、攝護腺癌、肺癌、胰臟癌等。依給藥途徑，藥物分為口服藥物和腸外藥物。按分銷管道分類，可分為醫院藥房、藥局和零售藥房以及線上提供者。從區域來看，分析包括北美、歐洲、亞太地區和拉丁美洲/中東/非洲。

主要發現

按藥物類型分類，抗代謝藥物預計在 2033 年佔據市場主導地位。

從應用來看，乳癌預計將在預測期內成為主要細分市場。

從給藥途徑來看，口服製劑預計在未來幾年將呈現最高成長。

從分銷管道來看，醫院藥房部門很可能在不久的將來引領全球細胞毒性藥物市場。

按地區分類，北美是 2023 年細胞毒性藥物市場的主要股東，預計在整個預測期內將保持主導地位。

該報告可以客製化（需要單獨的費用和時間表）。

  • 監管指引
  • 根據客戶興趣加入公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 擴大公司簡介列表
  • 歷史市場資料
  • 主要參與企業的詳細資料（Excel格式，包括位置、聯絡資訊、供應商/供應商網路等）

目錄

第1章簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 關鍵投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章細胞毒性藥物市場：依藥物類型

  • 市場概況
  • 烷化劑
  • 抗腫瘤抗生素
  • 抗代謝藥
  • 植物生物鹼
  • 其他

第5章細胞毒性藥物市場：依應用分類

  • 市場概況
  • 乳癌
  • 攝護腺癌
  • 肺癌
  • 胰臟癌
  • 其他

第6章 細胞毒性藥物市場：依給藥途徑

  • 市場概況
  • 口服劑
  • 胃腸外的

第7章 臨床有毒藥品市場：依通路

  • 市場概況
  • 醫院藥房
  • 藥局和零售藥局
  • 線上提供者

第8章細胞毒性藥物市場：按地區

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國細胞毒藥物市場
    • 加拿大細胞毒性藥物市場
    • 墨西哥細胞毒性藥物市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 德國細胞毒藥物市場
    • 法國細胞毒藥物市場
    • 英國細胞毒藥物市場
    • 義大利細胞毒藥物市場
    • 西班牙細胞毒藥物市場
    • 其他歐洲細胞毒性藥物市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 日本細胞毒藥物市場
    • 中國細胞毒藥物市場
    • 印度細胞毒性藥物市場
    • 澳洲細胞毒藥物市場
    • 韓國細胞毒藥物市場
    • 其他亞太細胞毒性藥物市場
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 巴西細胞毒性藥物市場
    • 沙烏地阿拉伯細胞毒性藥物市場
    • 南非細胞毒性藥物市場
    • 其他拉丁美洲/中東/非洲細胞毒性藥物市場

第9章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位（2023年）

第10章 公司簡介

  • Baxter
  • Cipla Ltd
  • Eli Lilly And Company
  • Fresenius Kabi AG
  • Johnson And Johnson
  • Novartis AG
  • Viatris Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
簡介目錄
Product Code: A324399

The cytotoxic drug market was valued at $15.8 billion in 2023, and is projected to reach $19.5 billion by 2033, growing at a CAGR of 2.1% from 2024 to 2033.

Cytotoxic drugs are chemotherapeutic agents that inhibit the growth of cancer cells by acting directly on the DNA or interfering with the biosynthesis of proteins. However, because they also affect healthy cells that divide frequently, such as those in the bone marrow, digestive tract, and hair follicles, their use is often accompanied by significant side effects. Despite these challenges, cytotoxic drugs remain essential in the treatment of various cancers, contributing to improved survival rates and better management of the disease.

The growth of the global cytotoxic drug market is majorly driven by alarming increase prevalence of cancer. According to the World Health Organization, cancer is the leading cause of death, and accounted for approximately 10 million deaths in 2020, thus fueling the demand for effective chemotherapy treatments, including cytotoxic drugs. Moreover, surge in geriatric population significantly contributes toward the growth of the global market. This is attributed to the fact that aged individuals are highly susceptible to cancer, leading to higher demand for cancer treatments. Furthermore, rise in awareness about early detection and treatment of cancer acts as the key driving force of the market. The American Cancer Society highlights that the five-year survival rate for cancer patients diagnosed at an early stage is 90%, compared to 20% for those diagnosed at a later stage, thereby highlighting the importance of early detection and the consequent use of cytotoxic drugs in treatment. Rise in emphasis on developing targeted cytotoxic therapies tailored to individual patients' genetic profiles to improve treatment efficacy and minimize side effects is further propelling the market growth. In addition, oral cytotoxic drugs are gaining high traction due to their convenience and ease of administration, allowing for better patient compliance and quality of life, thus augmenting the market growth. However, adverse effects associated with cytotoxic drugs, such as nausea, hair loss, and bone marrow suppression, limit their use, which hampers the growth of the global market. In addition, rise in awareness about more effective therapies such as targeted therapies, immunotherapies, and other innovative cancer treatments potentially reduce the demand for traditional cytotoxic drugs, which acts as the key deterrent factor of the market. On the contrary, innovations in drug formulation and delivery systems to enhance the efficacy and safety of cytotoxic drugs are expected to offer lucrative opportunities for the growth of the global market during the forecast period. For instance, recent studies have shown that new formulations of cytotoxic drugs, such as liposomal doxorubicin, can reduce side effects and improve patient outcomes. Clinical trials have demonstrated that these advanced formulations can enhance drug delivery to tumor sites by 30-40%.

The global cytotoxic drug market is segmented into drug type, application, route of administration, distribution channel, and region. On the basis of the drug type, the market is segregated into alkylating agents, antitumor antibiotics, antimetabolites, plant alkaloids, and others. As per application, it is classified into breast cancer, prostate cancer, lung cancer, pancreatic cancer, and others. By route of administration, it is bifurcated into oral and parenteral. According to distribution channel, it is fragmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By drug type, the antimetabolites segment is expected to dominate the market by 2033.

On the basis of application, breast cancer is anticipated to emerge as a leading segment during the forecast period.

Depending on route of administration, the oral segment is projected to exhibit the highest growth in the coming years.

As per distribution channel, the hospital pharmacies segment is likely to lead the lobal cytotoxic drug market in the near future.

Region wise, North America was the major shareholder in the cytotoxic drug market in 2023, and is expected to retain its dominance throughout the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global cytotoxic drug market include Baxter, Cipla Ltd, Eli Lilly and Company, Fresenius Kabi AG, Johnson & Johnson, Novartis AG, Viatris Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and strengthen their foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Drug Type

  • Alkylating Agents
  • Antitumor Antibiotics
  • Antimetabolites
  • Plant Alkaloids
  • Others

By Application

  • Breast Cancer
  • Prostate Cancer
  • Lung Cancer
  • Pancreatic Cancer
  • Others

By Route Of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Baxter
    • Cipla Ltd
    • Eli Lilly and Company
    • Fresenius Kabi AG
    • Johnson & Johnson
    • Novartis AG
    • Viatris Inc.
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: CYTOTOXIC DRUG MARKET, BY DRUG TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Drug Type
  • 4.2. Alkylating Agents
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Antitumor Antibiotics
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Antimetabolites
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Plant Alkaloids
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country
  • 4.6. Others
    • 4.6.1. Key Market Trends, Growth Factors and Opportunities
    • 4.6.2. Market Size and Forecast, By Region
    • 4.6.3. Market Share Analysis, By Country

CHAPTER 5: CYTOTOXIC DRUG MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Breast Cancer
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Prostate Cancer
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Lung Cancer
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Pancreatic Cancer
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country
  • 5.6. Others
    • 5.6.1. Key Market Trends, Growth Factors and Opportunities
    • 5.6.2. Market Size and Forecast, By Region
    • 5.6.3. Market Share Analysis, By Country

CHAPTER 6: CYTOTOXIC DRUG MARKET, BY ROUTE OF ADMINISTRATION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Route of Administration
  • 6.2. Oral
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Parenteral
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country

CHAPTER 7: CYTOTOXIC DRUG MARKET, BY DISTRIBUTION CHANNEL

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Distribution Channel
  • 7.2. Hospital Pharmacies
    • 7.2.1. Key Market Trends, Growth Factors and Opportunities
    • 7.2.2. Market Size and Forecast, By Region
    • 7.2.3. Market Share Analysis, By Country
  • 7.3. Drug Stores And Retail Pharmacies
    • 7.3.1. Key Market Trends, Growth Factors and Opportunities
    • 7.3.2. Market Size and Forecast, By Region
    • 7.3.3. Market Share Analysis, By Country
  • 7.4. Online Providers
    • 7.4.1. Key Market Trends, Growth Factors and Opportunities
    • 7.4.2. Market Size and Forecast, By Region
    • 7.4.3. Market Share Analysis, By Country

CHAPTER 8: CYTOTOXIC DRUG MARKET, BY REGION

  • 8.1. Market Overview
    • 8.1.1 Market Size and Forecast, By Region
  • 8.2. North America
    • 8.2.1. Key Market Trends and Opportunities
    • 8.2.2. Market Size and Forecast, By Drug Type
    • 8.2.3. Market Size and Forecast, By Application
    • 8.2.4. Market Size and Forecast, By Route of Administration
    • 8.2.5. Market Size and Forecast, By Distribution Channel
    • 8.2.6. Market Size and Forecast, By Country
    • 8.2.7. U.S. Cytotoxic Drug Market
      • 8.2.7.1. Market Size and Forecast, By Drug Type
      • 8.2.7.2. Market Size and Forecast, By Application
      • 8.2.7.3. Market Size and Forecast, By Route of Administration
      • 8.2.7.4. Market Size and Forecast, By Distribution Channel
    • 8.2.8. Canada Cytotoxic Drug Market
      • 8.2.8.1. Market Size and Forecast, By Drug Type
      • 8.2.8.2. Market Size and Forecast, By Application
      • 8.2.8.3. Market Size and Forecast, By Route of Administration
      • 8.2.8.4. Market Size and Forecast, By Distribution Channel
    • 8.2.9. Mexico Cytotoxic Drug Market
      • 8.2.9.1. Market Size and Forecast, By Drug Type
      • 8.2.9.2. Market Size and Forecast, By Application
      • 8.2.9.3. Market Size and Forecast, By Route of Administration
      • 8.2.9.4. Market Size and Forecast, By Distribution Channel
  • 8.3. Europe
    • 8.3.1. Key Market Trends and Opportunities
    • 8.3.2. Market Size and Forecast, By Drug Type
    • 8.3.3. Market Size and Forecast, By Application
    • 8.3.4. Market Size and Forecast, By Route of Administration
    • 8.3.5. Market Size and Forecast, By Distribution Channel
    • 8.3.6. Market Size and Forecast, By Country
    • 8.3.7. Germany Cytotoxic Drug Market
      • 8.3.7.1. Market Size and Forecast, By Drug Type
      • 8.3.7.2. Market Size and Forecast, By Application
      • 8.3.7.3. Market Size and Forecast, By Route of Administration
      • 8.3.7.4. Market Size and Forecast, By Distribution Channel
    • 8.3.8. France Cytotoxic Drug Market
      • 8.3.8.1. Market Size and Forecast, By Drug Type
      • 8.3.8.2. Market Size and Forecast, By Application
      • 8.3.8.3. Market Size and Forecast, By Route of Administration
      • 8.3.8.4. Market Size and Forecast, By Distribution Channel
    • 8.3.9. UK Cytotoxic Drug Market
      • 8.3.9.1. Market Size and Forecast, By Drug Type
      • 8.3.9.2. Market Size and Forecast, By Application
      • 8.3.9.3. Market Size and Forecast, By Route of Administration
      • 8.3.9.4. Market Size and Forecast, By Distribution Channel
    • 8.3.10. Italy Cytotoxic Drug Market
      • 8.3.10.1. Market Size and Forecast, By Drug Type
      • 8.3.10.2. Market Size and Forecast, By Application
      • 8.3.10.3. Market Size and Forecast, By Route of Administration
      • 8.3.10.4. Market Size and Forecast, By Distribution Channel
    • 8.3.11. Spain Cytotoxic Drug Market
      • 8.3.11.1. Market Size and Forecast, By Drug Type
      • 8.3.11.2. Market Size and Forecast, By Application
      • 8.3.11.3. Market Size and Forecast, By Route of Administration
      • 8.3.11.4. Market Size and Forecast, By Distribution Channel
    • 8.3.12. Rest of Europe Cytotoxic Drug Market
      • 8.3.12.1. Market Size and Forecast, By Drug Type
      • 8.3.12.2. Market Size and Forecast, By Application
      • 8.3.12.3. Market Size and Forecast, By Route of Administration
      • 8.3.12.4. Market Size and Forecast, By Distribution Channel
  • 8.4. Asia-Pacific
    • 8.4.1. Key Market Trends and Opportunities
    • 8.4.2. Market Size and Forecast, By Drug Type
    • 8.4.3. Market Size and Forecast, By Application
    • 8.4.4. Market Size and Forecast, By Route of Administration
    • 8.4.5. Market Size and Forecast, By Distribution Channel
    • 8.4.6. Market Size and Forecast, By Country
    • 8.4.7. Japan Cytotoxic Drug Market
      • 8.4.7.1. Market Size and Forecast, By Drug Type
      • 8.4.7.2. Market Size and Forecast, By Application
      • 8.4.7.3. Market Size and Forecast, By Route of Administration
      • 8.4.7.4. Market Size and Forecast, By Distribution Channel
    • 8.4.8. China Cytotoxic Drug Market
      • 8.4.8.1. Market Size and Forecast, By Drug Type
      • 8.4.8.2. Market Size and Forecast, By Application
      • 8.4.8.3. Market Size and Forecast, By Route of Administration
      • 8.4.8.4. Market Size and Forecast, By Distribution Channel
    • 8.4.9. India Cytotoxic Drug Market
      • 8.4.9.1. Market Size and Forecast, By Drug Type
      • 8.4.9.2. Market Size and Forecast, By Application
      • 8.4.9.3. Market Size and Forecast, By Route of Administration
      • 8.4.9.4. Market Size and Forecast, By Distribution Channel
    • 8.4.10. Australia Cytotoxic Drug Market
      • 8.4.10.1. Market Size and Forecast, By Drug Type
      • 8.4.10.2. Market Size and Forecast, By Application
      • 8.4.10.3. Market Size and Forecast, By Route of Administration
      • 8.4.10.4. Market Size and Forecast, By Distribution Channel
    • 8.4.11. South Korea Cytotoxic Drug Market
      • 8.4.11.1. Market Size and Forecast, By Drug Type
      • 8.4.11.2. Market Size and Forecast, By Application
      • 8.4.11.3. Market Size and Forecast, By Route of Administration
      • 8.4.11.4. Market Size and Forecast, By Distribution Channel
    • 8.4.12. Rest of Asia-Pacific Cytotoxic Drug Market
      • 8.4.12.1. Market Size and Forecast, By Drug Type
      • 8.4.12.2. Market Size and Forecast, By Application
      • 8.4.12.3. Market Size and Forecast, By Route of Administration
      • 8.4.12.4. Market Size and Forecast, By Distribution Channel
  • 8.5. LAMEA
    • 8.5.1. Key Market Trends and Opportunities
    • 8.5.2. Market Size and Forecast, By Drug Type
    • 8.5.3. Market Size and Forecast, By Application
    • 8.5.4. Market Size and Forecast, By Route of Administration
    • 8.5.5. Market Size and Forecast, By Distribution Channel
    • 8.5.6. Market Size and Forecast, By Country
    • 8.5.7. Brazil Cytotoxic Drug Market
      • 8.5.7.1. Market Size and Forecast, By Drug Type
      • 8.5.7.2. Market Size and Forecast, By Application
      • 8.5.7.3. Market Size and Forecast, By Route of Administration
      • 8.5.7.4. Market Size and Forecast, By Distribution Channel
    • 8.5.8. Saudi Arabia Cytotoxic Drug Market
      • 8.5.8.1. Market Size and Forecast, By Drug Type
      • 8.5.8.2. Market Size and Forecast, By Application
      • 8.5.8.3. Market Size and Forecast, By Route of Administration
      • 8.5.8.4. Market Size and Forecast, By Distribution Channel
    • 8.5.9. South Africa Cytotoxic Drug Market
      • 8.5.9.1. Market Size and Forecast, By Drug Type
      • 8.5.9.2. Market Size and Forecast, By Application
      • 8.5.9.3. Market Size and Forecast, By Route of Administration
      • 8.5.9.4. Market Size and Forecast, By Distribution Channel
    • 8.5.10. Rest of LAMEA Cytotoxic Drug Market
      • 8.5.10.1. Market Size and Forecast, By Drug Type
      • 8.5.10.2. Market Size and Forecast, By Application
      • 8.5.10.3. Market Size and Forecast, By Route of Administration
      • 8.5.10.4. Market Size and Forecast, By Distribution Channel

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top Winning Strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Top Player Positioning, 2023

CHAPTER 10: COMPANY PROFILES

  • 10.1. Baxter
    • 10.1.1. Company Overview
    • 10.1.2. Key Executives
    • 10.1.3. Company Snapshot
    • 10.1.4. Operating Business Segments
    • 10.1.5. Product Portfolio
    • 10.1.6. Business Performance
    • 10.1.7. Key Strategic Moves and Developments
  • 10.2. Cipla Ltd
    • 10.2.1. Company Overview
    • 10.2.2. Key Executives
    • 10.2.3. Company Snapshot
    • 10.2.4. Operating Business Segments
    • 10.2.5. Product Portfolio
    • 10.2.6. Business Performance
    • 10.2.7. Key Strategic Moves and Developments
  • 10.3. Eli Lilly And Company
    • 10.3.1. Company Overview
    • 10.3.2. Key Executives
    • 10.3.3. Company Snapshot
    • 10.3.4. Operating Business Segments
    • 10.3.5. Product Portfolio
    • 10.3.6. Business Performance
    • 10.3.7. Key Strategic Moves and Developments
  • 10.4. Fresenius Kabi AG
    • 10.4.1. Company Overview
    • 10.4.2. Key Executives
    • 10.4.3. Company Snapshot
    • 10.4.4. Operating Business Segments
    • 10.4.5. Product Portfolio
    • 10.4.6. Business Performance
    • 10.4.7. Key Strategic Moves and Developments
  • 10.5. Johnson And Johnson
    • 10.5.1. Company Overview
    • 10.5.2. Key Executives
    • 10.5.3. Company Snapshot
    • 10.5.4. Operating Business Segments
    • 10.5.5. Product Portfolio
    • 10.5.6. Business Performance
    • 10.5.7. Key Strategic Moves and Developments
  • 10.6. Novartis AG
    • 10.6.1. Company Overview
    • 10.6.2. Key Executives
    • 10.6.3. Company Snapshot
    • 10.6.4. Operating Business Segments
    • 10.6.5. Product Portfolio
    • 10.6.6. Business Performance
    • 10.6.7. Key Strategic Moves and Developments
  • 10.7. Viatris Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Key Executives
    • 10.7.3. Company Snapshot
    • 10.7.4. Operating Business Segments
    • 10.7.5. Product Portfolio
    • 10.7.6. Business Performance
    • 10.7.7. Key Strategic Moves and Developments
  • 10.8. Pfizer Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Key Executives
    • 10.8.3. Company Snapshot
    • 10.8.4. Operating Business Segments
    • 10.8.5. Product Portfolio
    • 10.8.6. Business Performance
    • 10.8.7. Key Strategic Moves and Developments
  • 10.9. Sun Pharmaceutical Industries Ltd.
    • 10.9.1. Company Overview
    • 10.9.2. Key Executives
    • 10.9.3. Company Snapshot
    • 10.9.4. Operating Business Segments
    • 10.9.5. Product Portfolio
    • 10.9.6. Business Performance
    • 10.9.7. Key Strategic Moves and Developments
  • 10.10. Teva Pharmaceutical Industries Ltd.
    • 10.10.1. Company Overview
    • 10.10.2. Key Executives
    • 10.10.3. Company Snapshot
    • 10.10.4. Operating Business Segments
    • 10.10.5. Product Portfolio
    • 10.10.6. Business Performance
    • 10.10.7. Key Strategic Moves and Developments